FDA panel backs Merck hepatitis drug
Links shared publicly online about this topic.
- 334total visits
FDA panel backs Merck hepatitis drug
View full resource at health.yahoo.net
Tags: Liver Condition, Hepatitis, Hepatitis C, Hepatitis C Medication, Drug, FDA, Merck & Co.
Most Recently Shared on April 27, 2011 at 3:39 pm By:
Merck pitches hepatitis C drug to U.S. FDA panel: An experimental drug for the liver-damaging hepatitis C virus ... http://bit.ly/g2QI1D
FDA panel backs Glaxo drug for rare cancer | ajc.com
ajc.com — “WASHINGTON — A panel of cancer experts rejected an experimental Merck drug for a rare form of cancer on Tuesday while recommending approval of a GlaxoSmithKline treatment for the same disease.” View full resource at ajc.com
Most Recently Shared on March 21, 2012 at 4:29 pm By:
Tom Heston, MD Doctor, Family Medicine Doctor, and Physician
FDA panel backs Glaxo drug for rare cancer - Atlanta Journal Constitution http://t.co/p4jwFZcO #medicine
FDA Backs Glaxo Drug For Rare Cancer | ThirdAge
thirdage.com — “ A panel of cancer experts rejected an experimental Merck drug for a rare form of cancer on Tuesday while recommending approval of a GlaxoSmithKline treatment for the same disease. Neither drug appears to help patients live longer, but panelists said Glaxo's Votrient helped delay tumor growth in the most vulnerable patients.” View full resource at thirdage.com
Most Recently Shared on March 21, 2012 at 12:19 am By:
FDA Backs Glaxo Drug For Rare Cancer http://t.co/QMfj2u64
FDA panel backs Glaxo drug for rare sarcoma cancer - Yahoo! News
news.yahoo.com — “From Yahoo! News: A panel of cancer experts rejected an experimental Merck drug for a rare form of cancer on Tuesday while recommending approval of a GlaxoSmithKline treatment for the same disease. Neither drug appears to help patients live longer, but panelists said Glaxo's Votrient helped delay tumor growth in the most vulnerable patients.” View full resource at news.yahoo.com
Most Recently Shared on March 20, 2012 at 6:57 pm By:
FDA panel backs Glaxo drug for rare sarcoma cancer: A panel of cancer experts voted against an experimental Merc... http://t.co/CS4hfxkn
FDA Panel Rejects Merck Drug for Sarcoma, but Backs Glaxo's Votrient - WSJ.com
online.wsj.com — “A federal advisory panel rejected an experimental Merck & Co. drug for use in patients with soft-tissue or bone sarcomas—on concerns that it didn't work well enough to offset potentially serious side effects—while backing a different drug from GlaxoSmithKline.” View full resource at online.wsj.com
Most Recently Shared on March 20, 2012 at 5:37 pm By:
FDA Panel Backs Glaxo Drug for Sarcoma http://t.co/Cc9B6D9P
FDA panel backs Glaxo drug for rare sarcoma cancer - Yahoo! News
news.yahoo.com — “From Yahoo! News: A panel of cancer experts rejected an experimental Merck drug for a rare form of cancer on Tuesday while recommending approval of a GlaxoSmithKline treatment for the same disease. Neither drug appears to help patients live longer, but panelists said Glaxo's Votrient helped delay tumor growth in the most vulnerable patients.” View full resource at news.yahoo.com
Most Recently Shared on March 20, 2012 at 5:29 pm By:
HealthTrendster Health Executive
FDA panel backs Glaxo drug for rare sarcoma cancer - A panel of cancer experts has backed the benefits of a GlaxoSmi... http://t.co/k7JJ13Oc
Merck’s cholesterol lowering drug gets FDA panel’s vote
news-medical.net — “A health advisors’ panel have unanimously backed the use of Merck & Co's cholesterol-lowering drug Vytorin for preventing stroke and other heart problems in patients with chronic kidney disease, but only in those patients not yet on dialysis. The panel voted 16-0 during a meeting today in Silver Spring, Maryland.” View full resource at news-medical.net
Most Recently Shared on November 4, 2011 at 12:49 am By:
Merck’s cholesterol lowering drug gets FDA panel’s vote: A health advisors’ panel have unanimously backed the us... http://t.co/G2OpFf7N
New Hepatitis C Drug Close to Gaining FDA Approval - Drugs.com MedNews
drugs.com — “Boceprevir, a new medication from Merck Co. that changes the way hepatitis C is treated, won unanimous support Wednesday from a panel of experts convened by the” View full resource at drugs.com
Most Recently Shared on May 1, 2011 at 9:51 pm By:
New Hepatitis C Drug Close to Gaining FDA Approval - http://bit.ly/kJqCjD
UPDATE: FDA Panel Backs Approval Of Vertex's Hepatitis C Drug - FoxNews.com
foxnews.com — “A Food and Drug Administration panel unanimously backed the approval of Vertex Pharmaceuticals Inc.'s proposed hepatitis C-drug telaprevir, saying it showed strong effectiveness, a day after also endorsing a similar product from Merck & Co.” View full resource at foxnews.com
Most Recently Shared on April 29, 2011 at 7:54 pm By:
Health,Fitness,Diet Health Business
UPDATE: FDA Panel Backs Approval Of Vertex's Hepatitis C Drug http://bit.ly/iSysXD
Hepatitis drugs: Boceprevir, telaprevir get FDA panels approval - latimes.com
latimes.com — “Two new hepatitis C drugs got unanimous backing from an FDA advisory panel this week” View full resource at latimes.com
Most Recently Shared on April 29, 2011 at 7:28 pm By:
LA Times Health News Health News
Advisory panel likes new hepatitis C drugs, which could expand options http://lat.ms/levTrT
FDA Panel Backs 2 Hepatitis C Drugs
webmd.com — “A major advance for treating hepatitis C is likely headed to market after government advisors backed two new drugs: telaprevir and boceprivir.” View full resource at webmd.com
Most Recently Shared on April 28, 2011 at 11:10 pm By:
FDA Panel Backs 2 Hepatitis C Drugs: A major advance for treating hepatitis C is likely headed to market after g... http://bit.ly/l3CzdU
HCV New Drug Research: FDA Panel Backs Approval Of Telaprevir For Hepatitis C
hepatitiscnewdrugs.blogspot.com — “HCV New Drug Research: FDA Panel Backs Approval Of Telaprevir For Hepatitis C” View full resource at hepatitiscnewdrugs.blogspot.com
Most Recently Shared on April 28, 2011 at 8:16 pm By:
Tina Banwart - HepatitisCNewDrugs Health Blog
FDA Panel Backs Approval Of Telaprevir For Hepatitis C http://goo.gl/fb/Vc4n9
New Hepatitis C Drug Close to Gaining FDA Approval - Yahoo! News
news.yahoo.com — “THURSDAY, April 28 (HealthDay News) -- Boceprevir, a new medication from Merck & Co. that changes the way hepatitis C is treated, won unanimous support Wednesday from a panel of experts convened by the U.S. Food and Drug Administration.” View full resource at news.yahoo.com
Most Recently Shared on April 28, 2011 at 6:19 pm By:
New Hepatitis C Drug Close to Gaining FDA Approval (HealthDay) http://yhoo.it/l8kEhm
New Hepatitis C Drug Close to Gaining FDA Approval - Drugs.com MedNews
drugs.com — “Boceprevir, a new medication from Merck Co. that changes the way hepatitis C is treated, won unanimous support Wednesday from a panel of experts convened by the” View full resource at drugs.com
Most Recently Shared on April 28, 2011 at 5:13 pm By:
Drugs and Devices OW OW Health
New Hepatitis C Drug Close to Gaining FDA Approval: THURSDAY, April 28 -- Boceprevir, a new medication fro... http://bit.ly/javHPN #drug
Merck wins unanimous FDA panel support for blockbuster boceprevir - FierceBiotech
fiercebiotech.com — “Merck ($MRK) walked away from yesterday's FDA panel review of the new hepatitis C drug boceprevir with a unanimous recommendation for marketing approval and a laundry list of suggested post-marketing Read more...” View full resource at fiercebiotech.com
Most Recently Shared on April 28, 2011 at 12:43 pm By:
John Carroll Health Communicator
FDA staff indicated support for telaprevir yesterday; agency sees telaprevir+boc as offering a new standard of care. http://bit.ly/illapF
Merck Wins U.S. FDA Panel--™s Backing for Hepatitis C Drug - Bloomberg
bloomberg.com — “Merck & Co. won a U.S. panel--™s backing to sell an experimental hepatitis C drug that cured more patients in clinical trials than current therapies.” View full resource at bloomberg.com
Most Recently Shared on April 28, 2011 at 11:20 am By:
John Carroll Health Communicator
In case you missed it, Merck gets unanimous panel support on boceprevir; list of suggested post-marketing studies. http://bloom.bg/iwYpxP
Advertisement
